Early Stage Parkinson’s Disease Detected

The usual method of visualizing brain structure utilizes a technique most of us are familiar with, called MRI. However, it is not sensitive enough to reveal the biological changes that take place in the brain of Parkinson patients, and at present is primarily only used to eliminate other possible diagnoses.

The Hebrew University of Jerusalem (HU) researchers, led by Professor Aviv Mezer, realized that the cellular changes in Parkinson’s could possibly be revealed by adapting a related technique, known as quantitative MRI (qMRI). Their method has enabled them to look at microstructures within the part of the deep brain known as the striatum – an organ which is known to deteriorate during the progress of Parkinson’s disease. Using a novel method of analysis, developed by Mezer’s doctoral student, Elior Drori, biological changes in the cellar tissue of the striatum were clearly revealed. Moreover, they were able to demonstrate that these changes were associated with the early stages of Parkinson’s and patients’ movement dysfunction. Their findings were published 12 July 2022 in the prestigious journal Science Advances.

qMRI achieves its sensitivity by taking several MRI images using different excitation energies – rather like taking the same photograph in different colors of lighting. The HU researchers were able to use their qMRI analysis to reveal changes in the tissue structure within distinct regions of the striatum. The structural sensitivity of these measurements could only have been previously achieved in laboratories examining the brain cells of patients post mortem. Not an ideal situation for detecting early disease or monitoring the efficacy of a drug!

Description: MRI images used for automatic detection of microstructural changes in early-stage Parkinson’s Disease (PD) patients. Marked in yellow are areas in the putamen where PD patients show tissue damage, compared to healthy controls.

When you don’t have measurements, you don’t know what is normal and what is abnormal brain structure, and what is changing during the progress of the disease,” explained Mezer. The new information will facilitate early diagnosis of the disease and provide “markers” for monitoring the efficacy of future drug therapies. “What we have discovered,” he continued “is the tip of the iceberg.” It is a technique that they will now extend to investigate microstructural changes in other regions of the brain. Furthermore, the team are now developing qMRI into a tool that can be used in a clinical setting. Mezer anticipates that is about 3-5 years down the line.

Drori further suggests that this type of analysis will enable identification of subgroups within the population suffering from Parkinson’s disease – some of whom may respond differently to some drugs than others. Ultimately, he sees this analysis “leading to personalized treatment, allowing future discoveries of drug with each person receiving the most appropriate drug”.

Source: https://www.bfhu.org/

New Blood Test Could Replace Biopsies

No one enjoys getting a biopsy, in which a tissue sample is surgically taken and analyzed in a lab for signs of disease, such as cancer. It’s not only unpleasant for the patient, but has clinical drawbacks: A biopsy doesn’t always extract the diseased tissue and isn’t helpful in detecting disease at early stages. These concerns have encouraged researchers to find less invasive and more accurate diagnostic methods. Prof. Nir Friedman and Ronen Sadeh of the Hebrew University of Jerusalem have developed a blood test that enables lab technicians to diagnose cancer and diseases of the heart and liver by identifying and determining the state of the dead cells throughout the body.

Millions of cells die every day and are replaced by new cells. When cells die, their DNA is fragmented. Some of these DNA fragments reach the blood and can be “read” by advanced DNA sequencing methods.

As a result of these scientific advancements, we understood that if this information is maintained within the DNA structure in the blood, we could use that data to determine the tissue source of dead cells and the genes that were active in those very cells. Based on those findings, we can uncover key details about the patient’s health,” Friedman said.

We are able to better understand why the cells died — whether it’s an infection or cancer — and based on that, be better positioned to determine how the disease is developing,” he said. Co-author Israa Sharkia added the simple blood test could “be administered often and quickly, allowing the medical staff involved to follow the presence or development of a disease more closely.”

A startup company, Senseera, has been established to pursue clinical testing of this innovative approach in partnership with major pharmaceutical companies.

The multi-author study published in Nature Biotechnology explains the test can even identify markers that may differentiate between patients with similar tumors, which could help physicians develop personalized treatments.

Source: https://www.zenger.news/